March 2026, Volume 4, Issue 3

Author

Souvik Nandy, Atul Seth, Sanjay Kumar Sharma, Bikram Bhardwaj, Akshay Malunjkar and Vipin Kumar Prajapati

Abstract

Introduction: Severe preeclampsia leads to significant maternal and neonatal morbidity and mortality if not treated in time. Existing treatment with MgSO4 using high dose Zuspan regimen can lead to toxicity associated with high dose of Mg. Our study compares low dose (Dhaka) with High dose (Zuspan) in efficacy of management of Severe preeclampsia. Methodology: It 's a pilot RCT with 30 cases in each arm. Group A received MgSO4 as per Dhaka Regimen and Group B received as per Zuspan regimen. Various maternal (Age, PoG, Proteinuria, Serum Mg levels, Eclampsia) and neonatal parameters (APGAR and NICU admission) were assessed. Results: In the present study average age in both the groups was 27 yrs with range between 20-39 years with no statistical difference. Commonest gestational age at presentation was between late preterm (34 wks - 36 wks) or early term (37-38 wks). Average BMI in low dose group (Group A) was 25.81 kg/m2 and that for high dose (Group B) was 24.39 kg/m2. Most of the maternal parameters in both the groups were comparable as the difference between them was statistically insignificant. There was no statistically significant difference in Fetal parameters. Results elaborated before show that the level of magnesium at 12th and 18th hour is less in Group A (Dhaka) in comparison to Group B (Zuspan). This reduced levels are statistically significant and also show that even with low dose MgSO4 there was no occurrence of eclampsia. Conclusion: It may be formulated that low dose Dhaka regime may be a safer than High dose Zuspan regime. Trial registration: CTRI/2019/05/018950.